MYTD Revenues: $18.6 billion (+15%)
MYTD Earnings: $4.1 billion (+29%)
Comments: Pharmaceutical sales increased 18% to $9.3 billion for the half-year. Growth was driven by key oncology drugs (MabThera/Rituxan, Herceptin, Avastin, Xeloda and Tarceva), up 22%, as well as metabolism, (Bonviva/Boniva up 127% to $304 million) transplantation and virology drugs, including increased Tamiflu sales for pandemic stockpiling. Lucentis, Genentech’s recently launched medicine for age-related blindness, was also a contributor to growth. Herceptin, Avastin and Xeloda approved for additional cancer indications in the EU and Japan.